Amivantamab Injection

$1,320

SKU: Amivantamab Injection Category: Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Amivantamab Injection, marketed under the brand name Rybrevant, is a groundbreaking bispecific monoclonal antibody designed to target both the epidermal growth factor receptor (EGFR) and MET receptor pathways. This dual-target approach offers a novel treatment avenue for patients with non-small cell lung cancer (NSCLC), particularly those harboring specific genetic mutations.

Mechanism of Action

Amivantamab Injection bispecific nature allows it to simultaneously inhibit EGFR and MET signaling pathways, both of which are implicated in tumor growth and progression. By binding to these receptors, Amivantamab Injection not only blocks the signals that promote cancer cell proliferation but also induces receptor degradation, thereby reducing the number of receptors available for signaling. Additionally, it engages the immune system to attack cancer cells through antibody-dependent cellular cytotoxicity.

Clinical Efficacy

The efficacy of Amivantamab Injection has been demonstrated in several clinical trials:

  • CHRYSALIS Study: This phase 1 study evaluated Amivantamab Injection in patients with advanced NSCLC harboring EGFR exon 20 insertion mutations who had progressed on platinum-based chemotherapy. The results showed a notable overall response rate, with many patients experiencing significant tumor shrinkage.
  • PAPILLON Study: A phase 3 trial that assessed the combination of Amivantamab Injection with chemotherapy in treatment-naïve patients with advanced NSCLC with EGFR exon 20 insertion mutations. The combination therapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone.

Administration and Dosage

Amivantamab Injection is administered via intravenous infusion. The dosing regimen is determined based on the patient’s body weight, with specific guidelines provided for those above and below certain weight thresholds. Recent developments have introduced a subcutaneous formulation, which offers a more convenient administration method, reducing infusion times from hours to minutes and decreasing the incidence of infusion-related reactions.

Side Effects

Common side effects associated with Amivantamab Injection include:

  • Rash
  • Infusion-related reactions
  • Skin infections around the nails
  • Muscle and joint pain
  • Shortness of breath
  • Nausea
  • Fatigue
  • Swelling in the lower legs, hands, or face
  • Mouth sores
  • Cough
  • Constipation
  • Vomiting
  • Changes in certain blood tests

Patients are advised to report any adverse effects to their healthcare provider promptly.

Regulatory Approvals

Amivantamab Injectionb received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, following progression on or after platinum-based chemotherapy. Subsequent approvals have expanded its use in combination with chemotherapy for first-line treatment in specific patient populations.

Conclusion

Amivantamab Injection represents a significant advancement in the treatment of NSCLC, offering hope to patients with specific genetic profiles. Its dual-target mechanism, combined with demonstrated clinical efficacy, positions it as a valuable option in the evolving landscape of cancer therapeutics.

 

Website : Jyotilifecar